Pharma regulator Health Canada has approved the use of a combination of two Novartis cancer therapies as targeted treatment to prevent recurrence of melanoma following surgery, also referred to as adjuvant treatment. 1 November 2018
Health Canada has granted a Notice of Compliance with conditions (NOCc) for Folotyn (pralatrexate) for the treatment of relapsed or refractory peripheral T-cell lymphoma (PTCL) from French privately held drugmaker Servier. 1 November 2018
Professional services firm focused on delivering digital transformation Genpact today announced it multi-year agreement with Germany’s Bayer, under which Genpact's Pharmacovigilance Artificial Intelligence (PVAI) suite of capabilities will be applied to Bayer's existing pharmacovigilance database and IT systems. 1 November 2018
Invokana (canagliflozin) has become the only oral diabetes drug approved in the USA to reduce the risk of heart attack, stroke or cardiovascular (CV) death. 31 October 2018
Johnson & Johnson has unveiled 96-week results from the pivotal Phase III AMBER study of Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide). 31 October 2018
Japanese drug major Astellas Pharma says that construction and renovation of new facilities for the research, development and manufacture of new drugs using new Modality/Technology has begun in Toyama and Tsukuba, Japan, as well as Massachusetts, USA. 31 October 2018
Shares in Jazz Pharmaceuticals were up 2% after two hours trading on Monday amid news of an expanded approval for Xyrem (sodium oxybate) oral solution in the USA. 29 October 2018
The Prix Galien USA Committee last night honored excellence in the biopharmaceutical and medical industry for research, development and innovation at its 12th annual Prix Galien Awards Gala, held at the American Museum of Natural History in New York City. 26 October 2018
A crackdown on fake medicines and medical devices by the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has netted a haul of more than 1 million doses worth in excess of £2 million ($2.6 million). 24 October 2018
UK-based NetScientific announced the completion of a $10 million Series A funding for Glycotest with Fosun Pharma, a Chinese pharmaceutical company with a market capitalization of HK$71 billion ($9.0 billion). 24 October 2018
Sun Pharmaceutical has launched its moderate-to-severe psoriasis treatment Ilumya (tildrakizumab-asmn) in the USA. The interleukin-23 (IL-23) inhibitor was approved in March based on a Phase III study which showed sustained skin clearance in 67.6% of patients. 24 October 2018
Drugmaker Mitsubishi Tanabe has teamed up with fellow Japanese firm Pharma Foods International in a research collaboration for the development of innovative monoclonal antibodies (mAbs) to treat autoimmune diseases. 23 October 2018
Germany-headquartered health care company Fresenius Kabi has announced the US launch of the Simplist injection of palonosetron hydrochloride. 23 October 2018
US drugmaker Purdue Pharma has entered into an agreement that provides it with an exclusive option to acquire SpineThera and gain worldwide rights to its products and technology platforms, including lead asset SX600, a novel dexamethasone containing microsphere that is in development for epidural administration for low back pain. 23 October 2018
Eisai and Merck & Co have started joint medical and marketing activities for the tyrosine kinase inhibitor Lenvima (lenvatinib mesylate) in Japan. 22 October 2018
A procurement team targeting exclusively imported cancer drugs formed by 14 Chinese provincial governments announced it got the lowest China prices for 48 cancer drugs. 22 October 2018
Ireland-incorporated Allergan has announced the completion of two positive safety and tolerability studies of ubrogepant for the acute treatment of migraine, with the news leading to a 1.6% rise to $191.00 in the firm’s share price by close of trading on Wednesday. 18 October 2018
Pharma major Takeda Pharmaceutical Company today says it has received unconditional clearance from the Japan Fair Trade Commission for the proposed acquisition of Ireland-headquartered rare disease specialist Shire that was announced on May 8, 2018. 18 October 2018
Merck KGaA, the German science and technology company, today inaugurated a new packaging center at its headquarters in Darmstadt, Germany. 17 October 2018
Shionogi has announced new data at IDWeek 2024 from PROVE (Retrospective Cefiderocol Chart Review), the largest global real-world evidence study of Fetroja/Fetcroja (cefiderocol), an innovative siderophore cephalosporin. 17 October 2024
Sanofi has entered into an agreement with Orano Med, a subsidiary of the Orano Group, to advance the development of radioligand therapies for rare cancers. 17 October 2024
ViiV Healthcare, the specialist HIV company majority owned by GSK, today announced the presentation of new real-world evidence and implementation data showing the effectiveness, adherence, and quality-of-life improvement of Apretude (cabotegravir long-acting (CAB LA)) for HIV pre-exposure prophylaxis (PrEP). 16 October 2024
Jaguar Health today announced the US launch of Gelclair, the only Food and Drug Administration (FDA)-approved mucoadhesive on the market indicated for the management of pain caused by oral mucositis 16 October 2024
Netherlands-based life sciences venture capital firm Forbion has raised more than 2 billion euros ($2.2 billion) across its two newest funds. 16 October 2024
The American Lung Association Research Institute has announced a $22 million research investment in 2024, marking one of the largest lung health research programs in the USA. 16 October 2024
US pharma major Eli Lilly has announced a strategic collaboration with two UK government departments and the devolved nations to tackle significant population health challenges, including exploring new models to better care for people living with obesity. 16 October 2024
TenNor Therapeutics, a Suzhou-based clinical-stage biotech company, has announced the initial closing of a series E financing round, raising over 300 million yuan ($41 million). 16 October 2024
Switzerland-based Novocure saw its shares rise 10% yesterday and leap a further 24% to $22.05 pre-market, after the company received a new US regulatory approval for its key product Optune Lua. 16 October 2024
Shares of Spanish drugmaker PharmaMar leapt more than 28% to 63.70 euros today, after it announced positive clinical trial findings for its combo lung cancer treatment, under development with USA-based Jazz Pharmaceuticals, which rose 4.2%. 15 October 2024
Novartis has discontinued an early Phase II trial of LTP001 in idiopathic pulmonary fibrosis (IPF). The company confirmed that the decision was not related to safety, with no issues emerging in the study. 15 October 2024
US pharma major Eli Lilly has announced plans to invest around 1.5 billion renminbi ($206 million) into expanding its manufacturing facility in Suzhou, China. 15 October 2024
Spanish dermatology specialist Almirall (BME: ALM) has announced the successful completion of the decentralized regulatory procedure in Europe for efinaconazole. 15 October 2024
French biopharma company Inventiva has announced financing of immediately 94.1 million euros ($103 million) and up to 348 million euros, subject to satisfaction of specified conditions. 15 October 2024
India's Central Drugs Standard Control Organization (CDSCO) has provided a favorable recommendation for its novel antibiotic Miqnaf (nafithromycin) discovered and developed for the treatment of community-acquired bacterial pneumonia (CABP) in adults. 14 October 2024
The Danish Medicines Council (Medicinrådet), responsible for evaluating and recommending new treatments for Denmark’s healthcare system, is facing a significant increase in processing times. 14 October 2024
The South African Health Products Regulatory Authority (SAHPRA) and the Australian Therapeutic Goods Administration (TGA) have signed a Memorandum of Understanding (MoU), which will strengthen collaboration between the two health product regulators. 14 October 2024
California-based AI company Suki has raised $70 million in new funding to accelerate the growth of its AI-powered voice solutions in healthcare. 11 October 2024